187 related articles for article (PubMed ID: 23621307)
1. Understanding the relationship between GSK-3 and Alzheimer's disease: a focus on how GSK-3 can modulate synaptic plasticity processes.
Medina M; Avila J
Expert Rev Neurother; 2013 May; 13(5):495-503. PubMed ID: 23621307
[TBL] [Abstract][Full Text] [Related]
2. New insights into the role of glycogen synthase kinase-3 in Alzheimer's disease.
Medina M; Avila J
Expert Opin Ther Targets; 2014 Jan; 18(1):69-77. PubMed ID: 24099155
[TBL] [Abstract][Full Text] [Related]
3. Glycogen synthase kinase-3 as a key regulator of cognitive function.
Fan X; Zhao Z; Wang D; Xiao J
Acta Biochim Biophys Sin (Shanghai); 2020 Mar; 52(3):219-230. PubMed ID: 32147679
[TBL] [Abstract][Full Text] [Related]
4. Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer's disease.
Medina M; Avila J
Curr Pharm Des; 2010; 16(25):2790-8. PubMed ID: 20698823
[TBL] [Abstract][Full Text] [Related]
5. GSK-3 and Tau: A Key Duet in Alzheimer's Disease.
Sayas CL; Ávila J
Cells; 2021 Mar; 10(4):. PubMed ID: 33804962
[TBL] [Abstract][Full Text] [Related]
6. Synaptotoxicity in Alzheimer's disease: the Wnt signaling pathway as a molecular target.
Inestrosa NC; Varela-Nallar L; Grabowski CP; Colombres M
IUBMB Life; 2007; 59(4-5):316-21. PubMed ID: 17505971
[TBL] [Abstract][Full Text] [Related]
7. [The relationship between the Wnt signaling and the psychiatric diseases].
Ferrero A; Cereseto M; Sifonios L
Vertex; 2006; 17(67):165-71. PubMed ID: 16847474
[TBL] [Abstract][Full Text] [Related]
8. [Involvement of Wnt signaling in hippocampal plasticity].
Markevich VA; Salozhin SV; Guliaeva NV
Ross Fiziol Zh Im I M Sechenova; 2012 Dec; 98(12):1460-70. PubMed ID: 23461192
[TBL] [Abstract][Full Text] [Related]
9. The role of GSK-3 in synaptic plasticity.
Peineau S; Bradley C; Taghibiglou C; Doherty A; Bortolotto ZA; Wang YT; Collingridge GL
Br J Pharmacol; 2008 Mar; 153 Suppl 1(Suppl 1):S428-37. PubMed ID: 18311157
[TBL] [Abstract][Full Text] [Related]
10. Axin: an emerging key scaffold at the synapse.
Chen Y; Fu AK; Ip NY
IUBMB Life; 2013 Aug; 65(8):685-91. PubMed ID: 23847014
[TBL] [Abstract][Full Text] [Related]
11. Amyloid-beta-induced neurotoxicity is reduced by inhibition of glycogen synthase kinase-3.
Koh SH; Noh MY; Kim SH
Brain Res; 2008 Jan; 1188():254-62. PubMed ID: 18031715
[TBL] [Abstract][Full Text] [Related]
12. The role of Akt-GSK-3beta signaling and synaptic strength in phencyclidine-induced neurodegeneration.
Lei G; Xia Y; Johnson KM
Neuropsychopharmacology; 2008 May; 33(6):1343-53. PubMed ID: 17637606
[TBL] [Abstract][Full Text] [Related]
13. Natural and synthetic bioactive inhibitors of glycogen synthase kinase.
Khan I; Tantray MA; Alam MS; Hamid H
Eur J Med Chem; 2017 Jan; 125():464-477. PubMed ID: 27689729
[TBL] [Abstract][Full Text] [Related]
14. Unravelling the Role of Glycogen Synthase Kinase-3 in Alzheimer's Disease-Related Epileptic Seizures.
Lin R; Jones NC; Kwan P
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32456185
[TBL] [Abstract][Full Text] [Related]
15. GSK-3: tricks of the trade for a multi-tasking kinase.
Doble BW; Woodgett JR
J Cell Sci; 2003 Apr; 116(Pt 7):1175-86. PubMed ID: 12615961
[TBL] [Abstract][Full Text] [Related]
16. A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S )-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer's disease.
Onishi T; Iwashita H; Uno Y; Kunitomo J; Saitoh M; Kimura E; Fujita H; Uchiyama N; Kori M; Takizawa M
J Neurochem; 2011 Dec; 119(6):1330-40. PubMed ID: 21992552
[TBL] [Abstract][Full Text] [Related]
17. Memantine inhibits calpain-mediated truncation of GSK-3 induced by NMDA: implications in Alzheimer's disease.
Goñi-Oliver P; Avila J; Hernández F
J Alzheimers Dis; 2009; 18(4):843-8. PubMed ID: 19661623
[TBL] [Abstract][Full Text] [Related]
18. Abeta exacerbates the neuronal dysfunction caused by human tau expression in a Drosophila model of Alzheimer's disease.
Folwell J; Cowan CM; Ubhi KK; Shiabh H; Newman TA; Shepherd D; Mudher A
Exp Neurol; 2010 Jun; 223(2):401-9. PubMed ID: 19782075
[TBL] [Abstract][Full Text] [Related]
19. Glycogen synthase kinase-3: a target for novel bipolar disorder treatments.
Gould TD; Zarate CA; Manji HK
J Clin Psychiatry; 2004 Jan; 65(1):10-21. PubMed ID: 14744163
[TBL] [Abstract][Full Text] [Related]
20. GSK-3β overexpression causes reversible alterations on postsynaptic densities and dendritic morphology of hippocampal granule neurons in vivo.
Llorens-Martín M; Fuster-Matanzo A; Teixeira CM; Jurado-Arjona J; Ulloa F; Defelipe J; Rábano A; Hernández F; Soriano E; Avila J
Mol Psychiatry; 2013 Apr; 18(4):451-60. PubMed ID: 23399915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
